<PubmedArticle xmlns:ns0="http://www.w3.org/1998/Math/MathML"><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39316321</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-9389</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Health care management science</Title><ISOAbbreviation>Health Care Manag Sci</ISOAbbreviation></Journal><ArticleTitle>The benefits (or detriments) of adapting to demand disruptions in a hospital pharmacy with supply chain disruptions.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10729-024-09686-3</ELocationID><Abstract><AbstractText>Supply chain disruptions and demand disruptions make it challenging for hospital pharmacy managers to determine how much inventory to have on-hand. Having insufficient inventory leads to drug shortages, while having excess inventory leads to drug waste. To mitigate drug shortages and waste, hospital pharmacy managers can implement inventory policies that account for supply chain disruptions and adapt these inventory policies over time to respond to demand disruptions. Demand disruptions were prevalent during the Covid-19 pandemic. However, it remains unclear how a drug's shortage-waste weighting (i.e., concern for shortages versus concern for waste) as well as the duration of and time between supply chain disruptions influence the benefits (or detriments) of adapting to demand disruptions. We develop an adaptive inventory system (i.e., inventory policies change over time) and conduct an extensive numerical analysis using real-world demand data from the University of Michigan's Central Pharmacy to address this research question. For a fixed mean duration of and mean time between supply chain disruptions, we find a drug's shortage-waste weighting dictates the magnitude of the benefits (or detriments) of adaptive inventory policies. We create a ranking procedure that provides a way of discerning which drugs are of most concern and illustrates which policies to update given that a limited number of inventory policies can be updated. When applying our framework to over 300 drugs, we find a decision-maker needs to update a very small proportion of drugs (e.g., <ns0:math><ns0:mrow><ns0:mo>&lt;</ns0:mo> <ns0:mn>5</ns0:mn> <ns0:mo>%</ns0:mo></ns0:mrow> </ns0:math> ) at any point in time to get the greatest benefits of adaptive inventory policies.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Czerniak</LastName><ForeName>Lauren L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0003-4379-2004</Identifier><AffiliationInfo><Affiliation>Department of Industrial and Operations Engineering, University of Michigan, 1205 Beal Ave, Ann Arbor, MI, 48109, USA. czernL@umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavieri</LastName><ForeName>Mariel S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Industrial and Operations Engineering, University of Michigan, 1205 Beal Ave, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daskin</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Industrial and Operations Engineering, University of Michigan, 1205 Beal Ave, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byon</LastName><ForeName>Eunshin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Industrial and Operations Engineering, University of Michigan, 1205 Beal Ave, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renius</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Michigan Medicine; Department of Pharmacy Services, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Burgunda V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leja</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Michigan Medicine; Department of Pharmacy Services, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tupps</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Michigan Medicine; Department of Pharmacy Services, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant DGE 1841052</GrantID><Agency>National Science Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Health Care Manag Sci</MedlineTA><NlmUniqueID>9815649</NlmUniqueID><ISSNLinking>1386-9620</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Healthcare</Keyword><Keyword MajorTopicYN="N">Inventory management</Keyword><Keyword MajorTopicYN="N">Operations management</Keyword><Keyword MajorTopicYN="N">Operations research</Keyword><Keyword MajorTopicYN="N">Pharmaceutical drugs</Keyword><Keyword MajorTopicYN="N">Simulation</Keyword><Keyword MajorTopicYN="N">Supply chain management</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316321</ArticleId><ArticleId IdType="doi">10.1007/s10729-024-09686-3</ArticleId><ArticleId IdType="pii">10.1007/s10729-024-09686-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Snyder LV, Atan Z, Peng P, Rong Y, Schmitt AJ, Sinsoysal B (2016) OR/MS models for supply chain disruptions: a review. IIE Trans 48(2):89–109</Citation></Reference><Reference><Citation>Aronson JK, Heneghan C, Ferner RE (2023) Drug shortages. part 2: Trends, causes and solutions. Br J Clin Pharmacol 89(10):2957–2963</Citation></Reference><Reference><Citation>Tucker EL, Cao Y, Fox ER, Sweet BV (2020) The drug shortage era: A scoping review of the literature 2001-2019. Clin Pharm Therap 108(6):1150–1155</Citation></Reference><Reference><Citation>Yang YT, Socal M, Bennett CL (2024) Addressing the drug-shortage crisis in oncology. JAMA Oncol 10(2):155–156</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.5722</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academies of Sciences, Engineering, &amp; and Medicine (NASEM) (2022) Building resilience into the nation’s medical product supply chains. The National Academies Press, Washington, DC</Citation></Reference><Reference><Citation>Kim KC, Rothenberger SD, Tadrous M, Hernandez I, Gellad WF, Devine JW, . . . Suda KJ (2024) Drug shortages prior to and during the covid-19 pandemic. JAMA Netw Open 7(4)</Citation></Reference><Reference><Citation>Phuong JM, Penm J, Chaar, B, Oldfield, LD, Moles, R (2019) The impacts of medication shortages on patient outcomes: a scoping review. PLoS ONE 14(5):1–17</Citation></Reference><Reference><Citation>Paul SK, Sarker R, Essam D (2016) Managing risk and disruption in productioninventory and supply chain systems: a review. J Ind Manag Optim 12(3):1009–1029</Citation></Reference><Reference><Citation>Shen B, Li Q (2017) Market disruptions in supply chains: a review of operational models. Int Trans Oper Res 24(4):697–711</Citation></Reference><Reference><Citation>Ivanov D, Dolgui A, Sokolov B, Ivanova M (2017) Literature review on disruption recovery in the supply chain. Int J Prod Res 55(20):6158–6174</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207543.2017.1330572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Meiser D, Liu Y, Bonner B, Lin L (2014) Kroger uses simulation-optimization to improve pharmacy inventory management. Interfaces 44(1):70–84</Citation></Reference><Reference><Citation>Little J, Coughlan B (2008) Optimal inventory policy within hospital space constraints. Health Care Manage Sci 11(2):177–183</Citation></Reference><Reference><Citation>Neve BV, Schmidt CP (2022) Point-of-use hospital inventory management with inaccurate usage capture. Health Care Manage Sci 25(1):126–145</Citation></Reference><Reference><Citation>Peterson R, Thomas J, Loiseau A (1972) Operational inventory control with stochastic, seasonal demand. Infor 10(1):81–93</Citation></Reference><Reference><Citation>Kim CO, Jun J, Baek JK, Smith RL, Kim YD (2005) Adaptive inventory control models for supply chain management. Int J Adv Manuf Technol 26:1184–1192</Citation></Reference><Reference><Citation>Eilon S, Elmaleh J (1970) Adaptive limits in inventory control. Manage Sci 16(8):B533–B548</Citation><ArticleIdList><ArticleId IdType="doi">10.1287/mnsc.16.8.B533</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillon M, Oliveira F, Abbasi B (2017) A two-stage stochastic programming model for inventory management in the blood supply chain. Int J Prod Econ 187:27–41</Citation></Reference><Reference><Citation>Kara A, Dogan I (2018) Reinforcement learning approaches for specifying ordering policies of perishable inventory systems. Expert Syst Appl 91:150–158</Citation></Reference><Reference><Citation>Rajendran S, Srinivas S (2020) Hybrid ordering policies for platelet inventory management under demand uncertainty. IISE Trans Healthc Syst Eng 10(2):113–126</Citation></Reference><Reference><Citation>Syawal HA, Alfares HK (2020) Inventory optimization for multiple perishable products with dynamic pricing, dependent stochastic demand, and dynamic reorder policy. 2020 Proc Ind Syst Eng Conf (ISEC) 1–5</Citation></Reference><Reference><Citation>Xu Y, Szmerekovsky J (2022) A multi-product multi-period stochastic model for a blood supply chain considering blood substitution and demand uncertainty. Health Care Manage Sci 25(3):441–459</Citation></Reference><Reference><Citation>Li Q, Yu P, Wu X (2016) Managing perishable inventories in retailing: replenishment, clearance sales, and segregation. Oper Res 64(6):1270–1284</Citation></Reference><Reference><Citation>Li J, Liu L, Hu H, Zhao Q, Guo L (2018) An inventory model for deteriorating drugs with stochastic lead time. Int J Environ Res Public Health 15(12):1–20</Citation></Reference><Reference><Citation>Franco C, Alfonso-Lizarazo E (2020) Optimization under uncertainty of the pharmaceutical supply chain in hospitals. Comput Chem Eng 135:1–13</Citation></Reference><Reference><Citation>Nguyen DH, Chen H (2019) Optimization of a perishable inventory system with both stochastic demand and supply: comparison of two scenario approaches. Croat Oper Res Rev 10(1):175–185</Citation></Reference><Reference><Citation>Nguyen DH, Chen H (2022) An effective approach for optimization of a perishable inventory system with uncertainty in both demand and supply. Int Trans Oper Res 29(4):2682–2704</Citation></Reference><Reference><Citation>Azghandi R (2019) Analytic models for effective planning for response to sudden disruptions. [Doctoral Dissertation] The Department of Mechanical and Industrial Engineering: Northeastern University 1–97</Citation></Reference><Reference><Citation>Schmitt TG, Kumar S, Stecke KE, Glover FW, Ehlen MA (2017) Mitigating disruptions in a multi-echelon supply chain using adaptive ordering. Omega 68:185–198</Citation></Reference><Reference><Citation>Atan Z, Rousseau M (2016) Inventory optimization for perishables subject to supply disruptions. Optim Lett 10:89–108</Citation></Reference><Reference><Citation>Czerniak LL, Daskin MS, Lavieri MS, Sweet BV, Leja J, Tupps MA, Renius K (2023) Closed-form (R,S) inventory policies for perishable inventory systems with supply chain disruptions. Infor 61(3):327–367</Citation></Reference><Reference><Citation>Saedi S, Kundakcioglu OE, Henry AC (2016) Mitigating the impact of drug shortages for a healthcare facility: an inventory management approach. Eur J Oper Res 251(1):107–123</Citation></Reference><Reference><Citation>Czerniak LL, Daskin MS, Lavieri MS, Sweet BV, Erley J, Tupps MA (2021) Improving simulation optimization run time when solving for periodic review inventory policies in a pharmacy. Proc 2021 Winter Simul Conf, 1–12</Citation></Reference><Reference><Citation>He Y, Wang S (2012) Analysis of production-inventory system for deteriorating items with demand disruption. Int J Prod Res 50(16):4580–4592</Citation></Reference><Reference><Citation>Rana RS, Kumar D, Mor RS, Prasad K (2021) Modelling the impact of demand disruptions on two warehouse perishable inventory policy amid COVID-19 lockdown. Int J Logist Res Appl 1–24</Citation></Reference><Reference><Citation>Uthayakumar R, Karuppasamy SK (2019) An EOQ model for deteriorating items with different types of time-varying demand in healthcare industries. J Anal 27:3–18</Citation></Reference><Reference><Citation>Ivanov D (2022) Lean resilience: AURA (Active Usage of Resilience Assets) framework for post-COVID-19 supply chain management. Int J Logist Manag 33(4)</Citation></Reference><Reference><Citation>Gebicki M, Mooney E, Chen S-J, Mazur LM (2014) Evaluation of hospital medication inventory policies. Health Care Manag Sci 17(3):215–229</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10729-013-9251-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker EL, Daskin MS, Sweet BV, Hopp, WJ (2020) Incentivizing resilient supply chain design to prevent drug shortages: policy analysis using two- and multi-stage stochastic programs. IISE Trans 52(4):394–412</Citation></Reference><Reference><Citation>Lee J, Lee HS, Shin H, Krishnan V (2021) Alleviating drug shortages: The role of mandated reporting induced operational transparency. Manage Sci 67(4):2326–2339</Citation><ArticleIdList><ArticleId IdType="doi">10.1287/mnsc.2020.3857</ArticleId></ArticleIdList></Reference><Reference><Citation>Shourabizadeh H, Kundakcioglu OE, Bozkir CDC, Tufekci MB, Henry AC (2023) Healthcare inventory management in the presence of supply disruptions and a reliable secondary supplier. Ann Oper Res 331(2):1149–1206</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10479-023-05620-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SR, Kona R, Faustino PJ, Gupta A, Taylor JS, Porter DA, Khan M (2014) United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: Progress and promise. J Pharm Sci 103(5):1331–1336</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.23925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni VG (2011) Introduction to modeling and analysis of stochastic systems. Springer New York</Citation></Reference><Reference><Citation>Snyder LV, Shen Z-JM (2019) Fundamentals of supply chain theory, 1st edn. Wiley</Citation></Reference><Reference><Citation>Czerniak LL (2023) Improving operational decision-making in hospital pharmacies in the presence of disruptions. [Doctoral Dissertation] The Department of Industrial and Operations Engineering: University of Michigan, 1–180</Citation></Reference><Reference><Citation>Jones, S. (2020). What are 503b outsourcing facilities? https://www.fagronsterile.com/newsroom/whatis-a-503b-compounding-pharmacy</Citation></Reference><Reference><Citation>Jia J, Zhao H (2017) Mitigating the us drug shortages through pareto-improving contracts. Prod Oper Manag 26(8):1463–1480</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/poms.12697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>